060590.KQ CTCBIO Inc

Healthcare Pharmaceuticals KOSDAQ
2,585 KRW
Close of Oct 30, 2026
2,525 5,610
Market cap
KRW 61.8B
P/E
8.3x
P/B
0.78x
ROE
15.5%
Dividend yield
-
Fundamental score
2.7/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 060590.KQ undervalued?

Graham number
Price2,585
Graham value4,803
Discount46.2%

060590.KQ trades 46.2% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CTCBIO Inc fundamental analysis

14 of 22 checks passed

ROE 1/2

Moderate return on equity (15.5%), between 10% and 20%.

ROA 1/1

Return on assets (8.1%) is above the industry median (3.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (162.1%) is above the industry median (6.6%).

Revenue Growth 0/2

Revenue shrank 9.2% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (11.7%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 8.1x against interest expense, well covered.

PE vs Market 1/1

PE (8.3x) is below the market median (11.3x).

PE vs Industry 1/1

PE (8.3x) is below the industry median (19.4x).

PBV 1/1

Price to book (0.8x) is below the industry median (0.8x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 6.5, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

CTCBIO Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CTCBIO Inc

CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diab…

Full company profile